Background: Infantile hemangiomas (IHs) are common childhood tumors.
Objective: Our study aimed to compare the efficacy and side effects of imiquimod and timolol maleate for the treatment of proliferating superficial IHs.
Methods: A total of 54 patients with superficial IHs were enrolled in this study. Each lesion was evenly divided into two parts. One part was treated with 5% imiquimod cream once every other day, and the other part was smeared with 0.5% timolol maleate eye drops thrice daily. After 16 weeks of treatment, the thickness, color and size of each lesion were measured, and the side effects were recorded.
Results: The efficacy rates for imiquimod and timolol maleate were 81.4 and 88.9%, respectively, but the difference between treatments was not significant. However, timolol maleate showed better effects for color involution, onset time and side effects than imiquimod.
Conclusion: Timolol maleate might be the first choice for the topical treatment of superficial IHs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000369164 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radius-Maumenee syndrome (idiopathic dilated episcleral vessels).
GMS Ophthalmol Cases
December 2024
Universidade Federal do Paraná (UFPR), Curitiba, Brazil.
Purpose: Idiopathic elevated episcleral venous pressure (IEEVP) or Radius-Maumenee syndrome (RMS) is a rare disease without any identified underlying cause. An increasing episcleral venous pressure (EVP) leads to raised intraocular pressure (IOP) and consequently glaucomatous damage of the optic nerve. The objective of this paper is to report this rare condition as well as its clinical management.
View Article and Find Full Text PDFColloid-Forming Prodrug-Hydrogel Composite Prolongs Lower Intraocular Pressure in Rodent Eyes after Subconjunctival Injection.
Adv Mater
January 2025
Department of Chemical Engineering & Applied Chemistry, University of Toronto, 200 College Street, Toronto, ON, M5S 3E5, Canada.
Colloidal drug aggregates (CDAs) are challenging in drug discovery due to their unpredictable formation and interference with screening assays. These limitations are turned into a strategic advantage by leveraging CDAs as a drug delivery platform. This study explores the deliberate formation and stabilization of CDAs for local ocular drug delivery, using a modified smallmolecule glaucoma drug.
View Article and Find Full Text PDFA water-soluble drug nanoparticle-loaded in situ gel for enhanced precorneal retention and its transduction mechanism of pharmacodynamic effects.
Int J Pharm
December 2024
Guangdong Provincial Key Laboratory for Research and Evaluation of Pharmaceutical Preparations, College of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China. Electronic address:
Article Synopsis
- Timolol maleate (TM) is commonly used to treat glaucoma, but traditional eye drops don't work well due to the eye's barriers.
- Researchers created a new formulation using nanoparticles (NPs) and an in situ gel (ISG) system to improve drug delivery and retention.
- The new formulation showed excellent safety, longer duration in the eye, and effectively lowered intraocular pressure for up to 12 hours, providing insights for future glaucoma treatments.
Development of Timolol Maleate-Loaded Poloxamer-co-Poly (acrylic acid) based hydrogel for controlled drug delivery.
PLoS One
December 2024
Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Prague, Czech Republic.
Free radical polymerization technique was used to formulate Poloxamer-188 based hydrogels for controlled delivery. A total of seven formulations were formulated with varying concentrations of polymer, monomer ad cross linker. In order to assess the structural properties of the formulated hydrogels, Fourier Transform Infrared Spectroscopy (FTIR), Thermogravimetric analysis (TGA), Differential Scanning Calorimetry (DSC), Scanning electron microscopy (SEM), and X-ray diffraction (XRD) were carried out.
View Article and Find Full Text PDFTimolol 0.5% Eye Drops for Essential Tremor: First Successful Case Report.
Mo Med
December 2024
Neurologist specializing in headache treatment, Kansas City, Missouri.
This paper presents a new treatment modality, timolol 0.5% eye drops either topical to normal eyes or preferably by a compounded nasal spray for episodic use in patients with mild to moderate essential tremor. This would primarily be patients wishing to damp their tremors on certain occasions or who were not able to tolerate daily oral beta blockers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!